SUMMARY

This summary aims to give you an overview of the information contained in this document. As this is a summary, it does not contain all the information that may be important to you. You should read the whole document before you decide to invest in the [**REDACTED**]. *There are risks associated with any investment. Some of the particular risks in investing in the* [**REDACTED**] *are set out in the section headed "Risk Factors" in this document. You should read that section carefully before you decide to invest in the* [**REDACTED**].

OVERVIEW

We are a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative vaccines. We have established a systematic product development framework that prioritizes key research areas and manages our R&D projects across different development stages. Our strategic focus centers on two key areas, namely, "superbug vaccines" (超級細菌疫苗) and "adult vaccines (成人疫苗)."

Distinct from many pre-revenue biotechnology companies, we have three commercialized products: Adsorbed Tetanus Vaccine (吸附破傷風疫苗), Haemophilus influenzae type b conjugate vaccine, or Hib Conjugate Vaccine (b型流感嗜血桿菌結合疫苗), and Group A and C meningococcal polysaccharide conjugate vaccine, or AC Conjugate Vaccine (A群C群腦膜炎球菌多糖結合疫苗). Leveraging our commercialization capabilities, our Adsorbed Tetanus Vaccine has maintained a dominant position in China during the Track Record Period. According to the CIC Report, in terms of revenue, our Adsorbed Tetanus Vaccine ranked first in the adsorbed tetanus vaccine market in China in 2025, with a market share of approximately 98.8%. According to the same report, the adsorbed tetanus vaccine market accounted for approximately 1.0% of the total vaccine market in China in 2025, in terms of revenue. Our portfolio of commercialized products serves as the cornerstone of our continued business development, generating stable cash flow and providing a solid foundation to fund and facilitate the development of our vaccine pipeline.

We have multiple vaccine pipelines targeting "superbugs", which exhibit significant resistance to multiple antibiotics and pose serious public health challenges globally due to limited or no effective treatment options. Our Class 1.1 superbug vaccine candidates are strategically developed to target five pathogens, comprising (i) recombinant five-antigen Staphylococcus aureus vaccine, or rFSAV (重組金葡菌疫苗), targeting Staphylococcus aureus, a "high priority" pathogen identified in both the WHO 2024 Superbug List and the WHO 2017 Superbug List; (ii) oral recombinant Helicobacter pylori vaccine (E. Coli), or rHPV (口服重組幽門螺桿菌疫苗(大腸桿菌)), targeting Helicobacter pylori, a "high priority" pathogen identified in the WHO 2017 Superbug List; (iii) recombinant four-antigen Pseudomonas aeruginosa vaccine, or rFPAV (重組銅綠假單胞菌疫苗), targeting Pseudomonas aeruginosa, a "high priority" pathogen identified in the WHO 2024 Superbug List and a "critical priority" in the WHO 2017 Superbug List; (iv) recombinant Acinetobacter baumannii vaccine, or rABV (重組鮑曼不動桿菌蛋白疫苗) , targeting Acinetobacter baumannii, a "critical priority" pathogen identified in both the WHO 2024 Superbug List and the WHO 2017 Superbug List; and (v) Group A Streptococcus vaccine, or GAS Vaccine (A群鏈球菌疫苗), targeting Group A Streptococcus identified as a "medium priority" pathogen in the WHO 2024 Superbug List.

Furthermore, we are actively exploring the development of "superbug" combination vaccines that can combine several of these bacterial targets, with the objective of achieving broader protection against multiple resistant infections. With no comparable commercialized product available globally targeting these superbugs, we anticipate a vast market for our superbug vaccine candidates. In addition, we plan to evaluate potential collaboration and out-licensing opportunities in overseas markets as part of our overall business development strategy.

During the Track Record Period, we experienced growth and business expansion, reflecting the success of our commercialization strategy and operational efficiency. Our revenue increased from RMB494.3 million in 2023 to RMB586.1 million in 2024 and to RMB700.1 million in 2025. Such financial performance provides a solid foundation for our continued investment in R&D and the advancement of our innovative pipeline, as well as our international expansion.

OUR COMMERCIALIZED PRODUCTS

Since our inception, we have built a comprehensive production and quality management system and established an expansive sales network covered 30 provinces, municipalities, and autonomous regions in China. As of the Latest Practicable Date, we had three commercialized products, all of which are Class II vaccines: Adsorbed Tetanus Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine. Our portfolio of commercialized products serves as the cornerstone of our continued business development, generating stable cash flow and allowing us to accumulate experience and expertise in product R&D, which in turn, provides a solid foundation to fund and facilitate the development of our vaccine pipeline products.

Adsorbed Tetanus Vaccine

Our Adsorbed Tetanus Vaccine is primarily used for post-exposure prophylaxis in individuals of all ages who have sustained trauma, and for pre-exposure immunization in high-risk populations, including pregnant women, to prevent maternal and neonatal tetanus. We are the first private enterprise in China to produce and sell adsorbed tetanus vaccine. Since its commercial launch in 2017, our Adsorbed Tetanus Vaccine has become our cornerstone product, establishing a leading market position in China.

During the Track Record Period, our revenue has been substantially dependent on the sales of our Adsorbed Tetanus Vaccine. In 2023, 2024 and 2025, revenue generated from our Adsorbed Tetanus Vaccine was RMB463.0 million, RMB535.8 million and RMB613.7 million, respectively, accounting for approximately 93.7%, 91.4% and 87.6% of our total revenue for the corresponding years, respectively. We expect that sales of our Adsorbed Tetanus Vaccine will continue to account for a significant portion of our total revenue in the near term.

Our reliance on this single product exposes us to certain risks, including risks relating to potential changes in market demand, the introduction of competing products, and a projected slowdown in the market growth rate for tetanus vaccines in China. To mitigate such risks, we have implemented a multi-faceted strategy aimed at diversifying our revenue streams over the mid to long term. Our principal strategies include: (i) advancing our late-stage pipeline products, particularly our rFSAV and Influenza Virus Split Vaccines, towards commercialization to enrich our product portfolio; (ii) leveraging our established sales network to create significant operational synergies for new product launches; (iii) developing a long-term pipeline of innovative vaccine candidates to build a sustainable and diversified product matrix; and (iv) maintaining the market position of our Adsorbed Tetanus Vaccine. However, there is no assurance that our strategies will be successfully implemented or that our pipeline products will be successfully developed or commercialized. For further details, see "Business — Our Reliance on Adsorbed Tetanus Vaccine and Our Mitigation Strategies".

Haemophilus Influenzae Type b Conjugate Vaccine

Our Hib Conjugate Vaccine is a polysaccharide conjugate vaccine for the prevention of invasive diseases caused by Haemophilus Influenzae Type b (b型流感嗜血桿菌), a leading cause of bacterial meningitis, pneumonia, and sepsis, particularly in young children. The vaccine is indicated for active immunization of infants and children from three months to five years of age. During the Track Record Period, revenue generated from our Hib Conjugate Vaccine was RMB27.3 million, RMB23.5 million and RMB18.8 million in 2023, 2024 and 2025, respectively, accounting for approximately 5.5%, 4.0% and 2.7% of our total revenue for the corresponding years, respectively.

Group A and C Meningococcal Polysaccharide Conjugate Vaccine

Our AC Conjugate Vaccine is indicated for the active immunization of infants and children from three months to five years of age for the prevention of epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A and C. These two serogroups are historically the predominant causes of meningococcal disease in China. During the Track Record Period, revenue generated from our AC Conjugate Vaccine was RMB3.9 million, RMB26.4 million and RMB65.3 million in 2023, 2024 and 2025, respectively, accounting for approximately 0.8%, 4.5% and 9.3% of our total revenue for the corresponding years, respectively.

For details, see "Business — Our Commercialized and Pipeline Products — Our Commercialized Products" in this document.

OUR PIPELINE PRODUCTS

Our pipeline is strategically focused on two key areas, namely, superbug vaccines and adult vaccines. All of our pipeline vaccine candidates are developed as Class II vaccines. Our lead candidate, the rFSAV, is under development for the prevention of infections caused by antibiotic-resistant Staphylococcus aureus.

Superbug Vaccine Candidates

Our Superbug Vaccine candidates include rFSAV, rHPV, rFPAV, rABV and GAS Vaccine, the details of which are set out below.

Our rFSAV is a multi-antigen subunit vaccine candidate for the prevention of infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, a pathogen designated by the WHO as a high-priority "superbug". The vaccine is being developed in collaboration with a leading comprehensive medical university in China (the "Key R&D Partner"). According to the CIC Report, it is currently the only vaccine candidate targeting Staphylococcus aureus globally that is undergoing a Phase III clinical trial. As of the Latest Practicable Date, we have completed enrollment of 6,014 planned subjects for such clinical trial. We anticipate completing the clinical trial and unblinding the data in the third quarter of 2026. Our rHPV is a vaccine candidate designed for the prevention of infection by Helicobacter pylori, a Gram-negative bacterium that colonizes the human stomach and upper duodenum. Helicobacter pylori infection is a major public health issue, recognized by the WHO as a Group 1 carcinogen due to its causal link to gastric cancer. This vaccine candidate is expected to be delivered orally, a route of administration we believe is optimal for inducing a protective mucosal immune response in the gastrointestinal tract. This product is another key component of our "superbug vaccine" strategy. Our rFPAV is a multi-component subunit vaccine candidate being developed for the prevention of infections caused by Pseudomonas aeruginosa. As a four-component recombinant protein-based vaccine, its design, which includes multiple distinct protein antigens, aims to elicit a broad immune response against a wide spectrum of Pseudomonas aeruginosa serotypes. By stimulating the production of specific functional antibodies, the vaccine is designed to prevent bacterial colonization, neutralize toxins, and facilitate immune clearance of the pathogen. According to the CIC Report, this multi-component formulation is the most component-rich rFPAV candidate in development globally as of

the Latest Practicable Date. Our rABV is a vaccine candidate for the prevention of infections caused by Acinetobacter baumannii, a Gram-negative bacterium that has emerged as one of the most critical threats in healthcare settings. According to the CIC Report, this vaccine candidate is the world's first active candidate targeting this pathogen to enter the formal research and development stage for this pathogen as of the Latest Practicable Date. Our GAS Vaccine is a peptide conjugate vaccine candidate being developed for the prevention of diseases caused by Group A Streptococcus, which is a human-exclusive pathogen responsible for a wide spectrum of illnesses, ranging from common infections like pharyngitis and impetigo to severe, life-threatening invasive diseases like necrotizing fasciitis and streptococcal toxic shock syndrome. It can also lead to serious post-infectious immune-mediated sequelae, most notably acute rheumatic fever and rheumatic heart disease.

For more details, see "Business — Our Commercialized and Pipeline Products — Our Pipeline Products — Our Superbug Vaccine Candidates" in this document.

Key Pipeline Candidates

In addition to our superbug vaccine candidates, we also develop (i) quadrivalent, trivalent and adjuvanted trivalent influenza virus split vaccines (MDCK cells) (四價/三價/三價佐劑流感病毒裂解疫苗(MDCK細胞)) (collectively, "Influenza Virus Split Vaccine Candidates"), and (ii) therapeutic monoclonal antibody candidates, which we collectively referred to herein as our key pipeline candidates. We are developing (i) a quadrivalent influenza virus split vaccine (MDCK cells), or Quadrivalent Influenza Vaccine (四價流感病毒裂解疫苗(MDCK細胞)), (ii) a trivalent influenza virus split vaccine (MDCK cells), or Trivalent Influenza Vaccine (三價流感病毒裂解疫苗(MDCK細胞)), and (iii) an adjuvanted trivalent influenza virus split vaccine (MDCK cells), or Adjuvanted Influenza Vaccine (三價佐劑流感病毒裂解疫苗(MDCK細胞)). These vaccine candidates are part of our strategic focus on the adult vaccine market. They are produced using a cell-culture technology platform as a superior alternative to traditional egg-based production.

We also develop (i) an anti-Staphylococcus aureus fully human monoclonal antibody (抗金黃色葡萄球菌單克隆抗體) based on the five protective antigens from our rFSAV, (ii) an anti-Pseudomonas aeruginosa fully human monoclonal antibody (抗銅綠假單胞菌單克隆抗體), built on four protective antigens from our rFPAV, and (iii) an anti-Tetanus toxin fully human monoclonal antibody (全人源破傷風單克隆抗體), which is based on our self-developed Adsorbed Tetanus Vaccine.

Additional Pipeline Candidates

In addition to our superbug vaccine candidates and key pipeline candidates, we are advancing a diversified vaccine pipeline targeting both adult and pediatric populations. These include our recombinant Zoster vaccine, or Recombinant Zoster Vaccine (重組帶狀疱疹疫苗), acellular Pertussis (three-component) vaccine and acellular Diphtheria-tetanus-pertussis (three-component) combined vaccine, or Acellular Pertussis (Three-Component) Vaccine and Acellular Diphtheria-tetanus-pertussis (Three-Component) Combined Vaccine (無細胞百日咳(三組分)疫苗及無細胞百白破(三組分)聯合疫苗), Group B meningococcal vaccine, or Group B Meningococcal Vaccine (B群腦膜炎球菌疫苗) and Meningococcal Groups A and C and Haemophilus B conjugate vaccine, or AC-Hib Conjugate Vaccine (AC-Hib聯合疫苗). These candidates form an important extension of our platform technology capabilities and reinforce our long-term focus on population-wide infectious disease prevention.

RESEARCH AND DEVELOPMENT

Our R&D capabilities are underpinned by our experienced R&D and management teams and a suite of proprietary and advanced technology platforms. Since our inception, we have continuously increased our R&D investment and expanded our technology platforms.

We leverage four integrated and synergistic core technology platforms that span the entire vaccine development value chain: (i) genetic engineering and multi-dimensional target vaccine design platform, (ii) polysaccharide-protein conjugation technology platform, (iii) integrated "molecule-to-human" vaccine efficacy evaluation platform, and (iv) digital and automated vaccine industrialization platform. These platforms cover the full process from early-stage target discovery and vaccine design, polysaccharide-protein conjugation process optimization, and comprehensive efficacy evaluation, to final-stage digital and automated industrialization. They provide a solid technological foundation for our existing and future product pipelines.

We have established two research centers in Chengdu and Chongqing. These centers provide the integrated infrastructure to advance vaccine candidates from initial concept and discovery through to GMP-compliant pilot-scale production and technology transfer for commercialization. As of December 31, 2025, we had a dedicated R&D team of 143 members. Our team is highly educated and experienced, with a deep understanding of vaccine development, from discovery through to industrialization.

PRODUCTION

We are capable of translating our R&D achievements into commercial-scale products. All our commercial and clinical-stage products are manufactured at our self-operated facilities, and we do not outsource any part of our core manufacturing processes. As of the Latest Practicable Date, our primary manufacturing base is located in Chengdu, Sichuan Province. The facilities are designed with a modular approach, housing dedicated and physically separated substances workshops for different vaccine types, such as bacterial, viral, and recombinant protein vaccines, to prevent cross-contamination and optimize process flows. All our production sites are self-owned. See "Business — Production" for further details.

OUR SUPPLIERS

During the Track Record Period, our major suppliers mainly included third-party CROs, marketing service providers, equipment providers and providers of technologies for product development. In 2023, 2024 and 2025, purchases from our five largest suppliers in each year of the Track Record Period amounted to RMB156.3 million, RMB215.8 million and RMB214.4 million, respectively, accounting for 31.7%, 32.5% and 32.1%, respectively, of our procurement for the corresponding years. In 2023, 2024 and 2025, purchases from our largest supplier in each year of the Track Record Period amounted to RMB43.6 million, RMB57.3 million and RMB52.6 million, respectively, accounting for 8.9%, 8.6% and 7.9%, respectively, of our total procurement for the corresponding years. See "Business — Our Suppliers" for further details.

OUR CUSTOMERS

Our customers primarily consist of CDCs at the country or district level across the PRC. In 2023, 2024 and 2025, the revenue generated from our five largest customers in each year of the Track Record Period amounted to RMB38.1 million, RMB34.4 million and RMB35.3 million, respectively, accounting for 7.7%, 5.9% and 5.0%, respectively, of our total revenue for the corresponding years. Revenue generated to our largest customer in each year of the Track Record Period amounted to RMB12.8 million, RMB10.4 million and RMB11.6 million, respectively, accounting for 2.6%, 1.8% and 1.7% of our total revenue for the corresponding years. See "Business — Our Customers" for further details.

SALES AND MARKETING

Our commercialized products and pipeline products are, and are expected to be, classified as non-immunization program vaccine (非免疫規劃疫苗), or Class II vaccines, in the PRC. Pursuant to the PRC Vaccine Administration Law, these products must be procured through provincial centralized public tender platforms, and direct sales to hospitals are prohibited. We deliver our vaccines to CDCs via qualified third-party cold-chain logistics providers, and the CDCs manage subsequent distribution to final POVs, such as community health centers or hospital-based clinics.

Our commercial operations are managed by our marketing center. As of December 31, 2025, our market center comprised 35 employees across functions including sales management, marketing, medical affairs, and logistics operations. To support our operations, we engage third-party marketing service providers to conduct academic promotion and market education activities to assist hospitals, which are the primary sites for trauma treatment, in obtaining the requisite qualifications from local health administrative departments to become legitimate POVs for our vaccine products.

COMPETITION

Vaccine markets in China and globally are highly competitive, rapidly evolving and characterized by technological advancement and innovation. We face actual and potential competition from companies, including large multinational and domestic pharmaceutical and biotechnology enterprises that have commercialized, are commercializing, or are developing vaccines targeting diseases that our commercialized and pipeline products target.

We believe we primarily compete on the strength of our commercialized vaccine products, especially our Adsorbed Tetanus Vaccine, our vaccine pipelines, our proprietary technology platforms, our research and development expertise, as well as our manufacturing facilities and processes. The degree of competition we face varies among vaccine types and targeted indications. Alternative treatments or prevention options for specific diseases may also limit the market potential and commercial success of our vaccine products. For further details relating to market opportunities and competition in respect of our products and pipelines, see "Industry Overview" and "Business — Our Commercialized and Pipeline Products."

OUR COMPETITIVE STRENGTHS AND STRATEGIES

We believe the following strengths have contributed to our success and will continue to differentiate us from our competitors: (i) proven commercialization capabilities, demonstrated by our success in leading the adult tetanus vaccine market in China; (ii) establishment of an innovative platform for Class 1.1 vaccines with the most comprehensive "superbug" vaccine pipeline in the world; (iii) cell-culture-based influenza vaccines addressing an unmet domestic supply need; (iv) R&D and collaboration capabilities supporting new vaccine development; (v) mature technology and industrialization platform supported by a strong talent reserve; (vi) international-standard vaccine production capability and a comprehensive quality management system; and (vii) a visionary and expected core management team.

We are committed to developing innovative vaccines, particularly in the high-need area of "superbug" infections. To achieve our long-term vision, we plan to implement the following key strategies: (i) accelerate the clinical development and commercialization of our core innovative pipeline; (ii) focus on our "superbug vaccine" development strategy and explore synergistic combination vaccine; (iii) upgrade our production capabilities to support commercialization and international standards; (iv) strengthen commercialization capabilities and deepen market penetration in China; (v) implement a dual-directional internationalization strategy; (vi) expand our pipeline from preventive vaccines to therapeutic antibodies; and (vii) reinforce our R&D model to drive sustainable innovation.

SUMMARY OF RISK FACTORS

Our operations involve certain risks and uncertainties, some of which are beyond our control and may affect your decision to invest in us and/or the value of your investment. See "Risk Factors" for details of our risk factors, which we strongly urge you to read in full before making an investment in our H Shares. Some of the major risks we face include (i) we have historically derived, and expect to continue to derive, a substantial portion of our revenue from a single product, our Adsorbed Tetanus Vaccine; (ii) if our bids in the public tender process are not successful or we fail to secure subsequent orders, our business may be adversely affected; (iii) our sales to CDCs may subject us to uncertainties associated with the government funding, budgeting and decision-making process; (iv) our vaccine products may become subject to national or other third-party reimbursement practices or unfavorable pricing regulations, which could harm our business; and (v) our pricing for vaccine products may limit market acceptance and result in reduced sales, adversely affecting our business and financial results.

SUMMARY HISTORICAL FINANCIAL INFORMATION

The following tables present our summary historical financial information for the periods or as of the dates indicated. This summary has been derived from our historical financial information included in the Accountants' Report as set out in Appendix I. The summary historical financial data set forth below should be read together with, and is qualified in its entirety by reference to, the historical financial information included in the Accountants' Report as set out in Appendix I, including the accompanying notes, and the information set forth in "Financial Information."

Summary of Consolidated Statements of Profit or Loss and Other Comprehensive Income

The table below presents a summary of our consolidated statement of profit or loss and other comprehensive income for the years indicated:

	Year ended December 31,		
	2023	2024	2025
	RMB'000	*RMB'000*	*RMB'000*
Revenue	**494,287**	**586,104**	**700,128**
Cost of revenue	(34,278)	(34,913)	(54,594)
Gross profit	**460,009**	**551,191**	**645,534**
Other net income/(loss)	(3,362)	3,651	(6,162)
Selling and distribution expenses	(257,806)	(302,900)	(380,936)
Administrative expenses	(59,730)	(70,570)	(65,543)
Research and development expenses	(114,729)	(134,235)	(132,904)
Impairment losses on trade and other receivables	(1,587)	(10,376)	(13,033)
Profit/(loss) from operations	**22,795**	**36,761**	**46,956**
Finance costs	(7,178)	(14,459)	(15,060)
Profit/(loss) before taxation	**15,617**	**22,302**	**31,896**
Income tax	(4,175)	(6,583)	(9,996)
Profit/(loss) and total comprehensive income for the year	**11,442**	**15,719**	**21,900**
Attributable to:			
Equity shareholders of the Company	17,556	20,757	22,262
Non-controlling interests	(6,114)	(5,038)	(362)
Earnings/(loss) per share			
Basic (RMB)	**0.04**	**0.05**	**0.05**
Diluted (RMB)	0.04	0.05	0.05

In 2023, 2024 and 2025, we recorded profit and total comprehensive income of RMB11.4 million, RMB15.7 million and RMB21.9 million, respectively. Our net profit increased by RMB4.3 million, from RMB11.4 million in 2023 to RMB15.7 million in 2024. This increase was primarily attributable to (i) an increase in revenue, mainly driven by continued growth in sales of our Adsorbed Tetanus Vaccine; and (ii) a significant increase in revenue from our AC Conjugate Vaccine, principally due to a significant increase in its selling price following the conclusion in 2024 of sales to the provincial immunization program in Anhui Province, which carried a lower selling price. The increase in net profit was partially offset by higher selling and distribution expenses incurred in line with our business growth and expanded sales activities. We recorded an increase of RMB6.2 million from a net profit of RMB15.7 million in 2024 to a net profit of RMB21.9 million in 2025, which was primarily driven by substantial growth in revenue, especially from our Adsorbed Tetanus Vaccine, as a result of the successful implementation of our targeted product enhancement and market penetration strategies. The increase in net profit was partially offset by higher selling and distribution expenses incurred in line with our business growth and expanded sales activities.

Revenue

The following table sets forth a breakdown of our revenue by commercialized product and type of customers, both in absolute amounts and as a percentage of total revenue, for the years indicated:

	For the years ended December 31,					
	2023		2024		2025	
	RMB'000	*%*	*RMB'000*	*%*	*RMB'000*	*%*
Adsorbed Tetanus Vaccine	**462,960**	**93.7**	**535,781**	**91.4**	**613,657**	**87.6**
– CDCs	420,599	85.1	508,021	86.7	579,314	82.7
– Blood product manufacturers	42,361	8.6	27,760	4.7	34,343	4.9
Hib Conjugate Vaccine	**27,265**	**5.5**	**23,497**	**4.0**	**18,763**	**2.7**
– CDCs	27,250	5.5	23,497	4.0	18,763	2.7
– Others**	15	*	–	–	–	–
AC Conjugate Vaccine	**3,883**	**0.8**	**26,422**	**4.5**	**65,347**	**9.3**
– CDCs	3,838	0.8	26,422	4.5	65,310	9.3
– Others**	45	*	–	–	37	*
Others[(1)]	**179**	**–**	**404**	**0.1**	**2,361**	**0.3**
– Blood product manufacturers	179	*	404	0.1	2,361	0.3
Total	**494,287**	**100.0**	**586,104**	**100.0**	**700,128**	**100.0**

Note:

(1) Others represent refined TT bulk, an intermediary product of adsorbed tetanus vaccine.

* less than 0.1%

** Represents highly isolated transactions conducted on a very limited and non-recurring basis with entities that were developing or conducting clinical trials for their own vaccine candidates, and purchased our Hib Conjugate Vaccine and AC Conjugate Vaccine to serve as clinical trial control samples. We do not actively market or seek to sell our products to these entities.

The following table sets forth a breakdown of our sales volume and average selling price by commercialized product and type of customers for the years indicated:

	For the years ended December 31,					
	2023		2024		2025	
	Sales volume	ASP	Sales volume	ASP	Sales volume	ASP
	('000 doses)	*(RMB/ dose)*	*('000 doses)*	*(RMB/ dose)*	*('000 doses)*	*(RMB/ dose)*
Adsorbed Tetanus Vaccine	3,148	147	3,363	159	3,830	160
– CDCs	2,418	174	2,844	179	3,322	174
– Blood product manufacturers	730	58	519	53	508	68
Hib Conjugate Vaccine	253	108	219	107	179	105
– CDCs	252	108	219	107	179	105
– Others	1	103	–	–	–	–
AC Conjugate Vaccine	319	12	252	105	415	157
– CDCs	318	12	252	105	414	158
– Others	1	151	–	–	1	158

Gross Profit and Gross Profit Margin

The table below sets forth our gross profit and gross profit margin by product and type of customers for the years indicated:

	For the years ended December 31,					
	2023		2024		2025	
	Gross Profit	Gross Profit Margin	Gross Profit	Gross Profit Margin	Gross Profit	Gross Profit Margin
	RMB'000	*%*	*RMB'000*	*%*	*RMB'000*	*%*
Adsorbed Tetanus Vaccine	**442,440**	**95.6**	**512,041**	**95.6**	**576,974**	**94.0**
– CDCs	404,401	96.1	487,596	96.0	547,090	94.4
– Blood product manufacturers	38,039	89.8	24,445	88.1	29,884	87.0
Hib Conjugate Vaccine	**21,183**	**77.7**	**18,859**	**80.3**	**15,085**	**80.4**
– CDCs	21,169	77.7	18,859	80.3	15,085	80.4
– Others	14	93.3	–	–	–	–
AC Conjugate Vaccine	**(3,731)**	**(96.1)**	**20,150**	**76.3**	**52,885**	**80.9**
– CDCs	(3,775)	(98.4)	20,150	76.3	52,849	80.4
– Others	44	97.8	–	–	36	97.3
Others	**117**	**65.4**	**141**	**34.9**	**590**	**25.0**
– Blood product manufacturers	117	65.4	141	34.9	590	25.0
Total	**460,009**	**93.1**	**551,191**	**94.0**	**645,534**	**92.2**

Our revenue increased by RMB114.0 million, or 19.5%, from RMB586.1 million in 2024 to RMB700.1 million in 2025, which was primarily driven by the substantial growth in revenue from our Adsorbed Tetanus Vaccine and AC Conjugate Vaccine. This followed an increase in revenue of RMB91.8 million, or 18.6%, from RMB494.3 million in 2023 to RMB586.1 million in 2024, which was primarily attributable to the continued growth in revenue from our key commercialized product, Adsorbed Tetanus Vaccine, and a significant increase in revenue from our other vaccine products. Meanwhile, our gross profit increased by RMB94.3 million, or 17.1%, from RMB551.2 million in 2024 to RMB645.5 million in 2025, with our overall gross profit margin decreasing from 94.0% to 92.2% for the same periods; this decrease was primarily due to (i) a lower gross profit margin from

our Adsorbed Tetanus Vaccine; and (ii) a change in product mix towards a higher proportion of sales from our AC Conjugate Vaccine, which carries a lower gross profit margin compared to our Adsorbed Tetanus Vaccine. Our gross profit increased by RMB91.2 million, or 19.8%, from RMB460.0 million in 2023 to RMB551.2 million in 2024, while our overall gross profit margin increased from 93.1% in 2023 to 94.0% in 2024, primarily due to the significant margin recovery for our AC Conjugate Vaccine. See "Financial Information — Statements of Profit or Loss and Comprehensive Income" in this document for details.

Summary of Consolidated Statements of Financial Position

The table below sets forth the breakdown of our current assets and current liabilities as of the dates indicated:

	As of December 31,		
	2023	**2024**	**2025**
	RMB'000	*RMB'000*	*RMB'000*
Non-current assets	678,701	896,441	1,018,341
Current assets	931,190	908,144	996,334
Current liabilities	481,251	596,765	750,557
Net current assets	**449,939**	**311,379**	**245,777**
Total assets less current liabilities	**1,128,640**	**1,207,820**	**1,264,118**
Non-current liabilities	197,877	274,318	360,138
Net assets	**930,763**	**933,502**	**903,980**
Total equity attributable to equity shareholders of the Company	916,904	924,681	903,678
Non-controlling interests	13,859	8,821	302
Total equity	**930,763**	**933,502**	**903,980**

Our net current assets decreased from RMB449.9 million as of December 31, 2023 to RMB311.4 million as of December 31, 2024. The decrease in net current assets was primarily due to (i) a decrease in our total current assets, which was primarily attributable to a decrease in cash and cash equivalents as we utilized cash to pay for clinical trial fees, make fixed asset investments and purchase new wealth management products; and (ii) an increase in our total current liabilities, primarily due to (a) an increase in trade and other payables, mainly reflecting higher payables for promotion service fees and raw materials; and (b) an increase in bank loans to support our working capital needs.

Our net current assets decreased from RMB311.4 million as of December 31, 2024 to RMB245.8 million as of December 31, 2025. The decrease in net current assets was primarily due to a significant increase in our total current liabilities that outpaced the growth in our total current assets, reflecting (i) an increase in our total current liabilities, primarily due to an increase in trade and other payables, mainly reflecting higher payables for the continued construction of our production facilities, increased marketing service fees, and the accrual of [**REDACTED**]-related expenses, partially offset by a decrease in bank loans following scheduled repayments; and (ii) an increase in our total current assets, which was primarily driven by (a) an increase in trade and other receivables, reflecting our continued business expansion and the recognition of [**REDACTED**] expenses, and (b) an increase in cash and cash equivalents, partially offset by a decrease in inventories as we strategically consumed existing raw materials and sold accumulated finished goods.

As of December 31, 2023, 2024 and 2025, our net assets amounted to RMB930.8 million, RMB933.5 million and RMB904.0 million, respectively. Our net assets remained relatively stable at RMB930.8 million and RMB933.5 million as of December 31, 2023 and 2024, respectively. Our net assets decreased from RMB933.5 million as of December 31, 2024 to RMB904.0 million as of December 31, 2025, mainly due to acquisition of non-controlling interests of a subsidiary of RMB39.1 million, partially offset by profit and total comprehensive income in 2025 of RMB21.9 million.

See "Financial Information — Description of Certain Key Items from Our Consolidated Statements of Financial Position" in this document for details.

Summary of Consolidated Cash Flow Statements

The table below sets forth a summary of our cash flows for the periods indicated:

	For the year ended December 31,		
	2023	2024	2025
	RMB'000	*RMB'000*	*RMB'000*
Net cash (used in)/generated from operating activities	49,808	(5,737)	105,447
Net cash used in investing activities	(78,843)	(223,934)	(83,346)
Net cash generated from financing activities	123,459	91,913	(14,702)
Net increase/(decrease) in cash and cash equivalents	94,424	(137,758)	7,399
Cash and cash equivalents at beginning of the year	261,111	355,535	217,777
Cash and cash equivalents at end of the year	**355,535**	**217,777**	**225,176**

We recorded an operating net cash outflow of RMB5.7 million in 2024. This net cash outflow was primarily attributable to (i) profit before taxation of RMB22.3 million; (ii) positive total adjustments before movements in working capital of RMB75.4 million, primarily reflecting (a) RMB31.2 million of positive adjustments for depreciation of property and equipment, (b) RMB14.5 million of positive adjustments for finance costs, and (c) RMB10.4 million of positive adjustments for impairment losses on trade and other receivables; (iii) negative movements in working capital of RMB98.2 million, primarily reflecting (a) an RMB94.2 million increase in trade and other receivables and (b) an RMB26.5 million increase in inventories, partially offset by an RMB20.7 million increase in trade and other payables; and (iv) PRC corporate income tax paid of RMB5.3 million.

In view of our net operating cash outflows in 2024, we have implemented a series of comprehensive management measures which we believe have successfully contributed to our net operating cash inflows in 2025, including (i) strengthening cash flow planning and regular monitoring through a structured budget process to ensure stable liquidity, supported by regular internal meetings between our senior management and operational departments to review our financial performance, alongside annual reporting to the Board; (ii) driving additional cash inflows by expanding our business scale, increasing revenue, and actively market new products or formulation to establish new growth drivers; (iii) enhancing operational efficiency and cost control by maintaining prudent staffing levels and minimizing production waste through upgrades to our existing production lines; (iv) optimizing inventory management to manage our inventory turnover days by conducting regular aging analyses and enhancing our prompt delivery capabilities; and (v) improving working capital management efficiency by (a) enhancing trade and other receivables management through regular aging analyses, refined credit assessment mechanisms, and proactive collection actions to recover overdue balances, and (b) strengthening ongoing communication and close follow-ups with customers regarding the timely settlement of outstanding balances. See "Financial Information — Liquidity and Capital Resources — Cash Flow Analysis" in this document for more information.

LISTING ON THE SSE STAR MARKET

In June 2021, we completed the initial public offering and listing of our A Shares on the SSE STAR Market (stock code: 688319), pursuant to which we issued an aggregate of 40,530,000 A Shares, accounting for approximately 10.0% of our Company's share capital immediately following the A Share listing.

OUR SINGLE LARGEST GROUP OF SHAREHOLDERS

As of the Latest Practicable Date, Shanghai Wushan, Mr. Fan Shaowen and Dr. Fan Fan directly held 60,216,322, 15,638,795 and 30,546,020 A Shares, respectively, accounting for approximately 14.84%, 3.85% and 7.53% of the issued share capital of our Company, respectively. Meanwhile, Mr. Fan Shaowen held approximately 47.22% of Shanghai Wushan and Dr. Fan Fan, who is the daughter of Mr. Fan Shaowen, held approximately 6.78% of Shanghai Wushan. On August 17, 2020, Mr. Fan Shaowen and Dr. Fan Fan entered into the Concert Parties Agreement, pursuant to which (i) it was confirmed that Mr. Fan Shaowen and Dr. Fan Fan, by virtue of their relationship as father and daughter, have been acting in concert since April 29, 2015 when Dr. Fan Fan became a shareholder of our Company; (ii) they agreed to continue to act in concert in relation to the operational development of our Company. Therefore, Shanghai Wushan, Mr. Fan Shaowen and Dr. Fan Fan are regarded as the Single Largest Group of Shareholders of our Company.

Accordingly, the Single Largest Group of Shareholders was entitled to exercise voting rights attached to the 106,401,137 A Shares, representing approximately 26.22% of the total issued share capital of our Company as of the Latest Practicable Date. Immediately following the completion of the [**REDACTED**], the Single Largest Group of Shareholders will be interested in approximately [**REDACTED**]% of our total share capital (assuming the [**REDACTED**] and the [**REDACTED**] are not exercised and no changes are made to our issued share capital between the Latest Practicable Date and the [**REDACTED**]) or approximately [**REDACTED**]% of our total share capital (assuming the [**REDACTED**] and the [**REDACTED**] are exercised in full).

USE OF [REDACTED]

Assuming that the [**REDACTED**] and the [**REDACTED**] are not exercised, after deducting the [**REDACTED**] commissions and other estimated [**REDACTED**] expenses payable by us in connection with the [**REDACTED**], and assuming an [**REDACTED**] of HK$[**REDACTED**] per H Share (being maximum [**REDACTED**]), we estimate that we will receive net [**REDACTED**] of approximately HK$[**REDACTED**] million from the [**REDACTED**].

We intend to use the net [**REDACTED**] from the [**REDACTED**] for the following purposes including (i) approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be allocated to the preclinical and clinical development of our rHPV candidate; (ii) approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be allocated to fund the clinical development and expansion of indications for our rFSAV; (iii) approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be allocated to the strategic upgrade of our production facilities to support the large-scale commercialization of our innovative vaccine pipelines and to ensure our facilities comply with international manufacturing standards; (iv) approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be allocated to expedite the clinical development of our cell-based influenza vaccine portfolio; (v) approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be allocated to the development and in-licensing of novel drug delivery systems; (vi) approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be allocated to the research and development of our therapeutic monoclonal antibody pipeline; (vii) approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be allocated to fund our global market expansion and international collaborations, in line with our dual-directional internationalization strategy; and (viii) approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used for working capital and other general corporate purposes.

APPLICATION FOR [REDACTED] ON THE STOCK EXCHANGE

We are applying for the [**REDACTED**] under Rule 8.05(3) of the Listing Rules and satisfy the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules with reference to (i) our revenue in 2025, being RMB700.1 million, which is over HK$500 million required by Rule 8.05(3) of the Listing Rules; and (ii) our expected market capitalization at the time of [**REDACTED**], which, based on the maximum [**REDACTED**] of HK$[**REDACTED**], exceeds HK$4 billion.

DIVIDENDS

Our Company does not maintain a fixed dividend distribution ratio. During the Track Record Period, we declared or paid cash dividends to our shareholders. On June 19, 2024, based on the total number of shares registered as of the record date for the distribution plan, our Board of Directors declared cash dividends to be distributed to our Company's A-share shareholders, with a cash dividend of RMB0.038 per share (tax inclusive). Based on the total number of shares as of the record date for the distribution plan, which was 406,158,000 shares, the cash dividend amount was RMB15,434,000 (tax inclusive). This dividend was fully paid on June 25, 2024, and was funded by our Company's internal cash flow. Our Board of Directors was of the opinion that the dividend plan was in line with our Company's actual situation and conducive to its sustainable development. Our PRC Legal Advisers have advised us that, based on their review, the dividend distribution by our Company during the Track Record Period was determined based on the parent company's distributable profits and was in compliance with the requirements under the applicable PRC laws and regulations and the Articles of Association. For further details, please see "Financial Information — Dividends".

[REDACTED] EXPENSES

Our [**REDACTED**] expenses mainly include [**REDACTED**] fees and commissions and professional fees paid to legal advisers and service providers for their services rendered in relation to the [**REDACTED**]. Based on an indicative [**REDACTED**] of HK$[**REDACTED**] per [**REDACTED**] (being the maximum [**REDACTED**]), we expect to incur [**REDACTED**] expenses of approximately RMB[**REDACTED**] million assuming the [**REDACTED**] and [**REDACTED**] are not exercised). Among the total estimated [**REDACTED**] expenses, approximately RMB[**REDACTED**] million is directly attributable to the issue of our Shares and will be accounted for as a deduction from equity upon the completion of the [**REDACTED**]. The remaining approximately RMB[**REDACTED**] million will be expensed in our consolidated statements of profit or loss and other comprehensive income. The [**REDACTED**] expenses above are the best estimate as of the Latest Practicable Date and for reference only and the actual amount may differ from this estimate. For further details, please see "Financial Information — [**REDACTED**] Expenses."

[REDACTED] STATISTICS

	Based on the maximum [REDACTED] of HK$[REDACTED] per [REDACTED]
Market capitalization of the H Shares[(1)]	HK$[REDACTED]
Market capitalization of the Shares[(2)]	HK$[REDACTED]
Unaudited [**REDACTED**] adjusted consolidated net tangible assets per Share[(3)]	HK$[REDACTED]

Notes:

(1) The total market capitalization of the H Shares is calculated based on [**REDACTED**] H Shares to be issued pursuant to the [**REDACTED**] (assuming the [**REDACTED**] and the [**REDACTED**] are not exercised).

(2) The total market capitalization of our Company is calculated based on (i) 405,708,900 A Shares in issue as of the Latest Practicable Date at the average closing price of the A Shares of our Company for the five trading days immediately preceding the Latest Practicable Date at RMB[36.25] (or approximately HK$[41.69]) per Share; and (ii) the expected market capitalization of our H Shares at [**REDACTED**] (assuming the [**REDACTED**] and the [**REDACTED**] are not exercised).

(3) The unaudited [**REDACTED**] adjusted net tangible assets per Share is arrived at on the basis that [**REDACTED**] shares (being [405,708,900] Shares in issue as of December 31, 2025 and [**REDACTED**] H Shares to be issued pursuant to the [**REDACTED**], deducting [299,600] unvested restricted shares under 2023 Share Award Scheme as of December 31, 2025) were in issue immediately following the completion of the [**REDACTED**], assuming the [**REDACTED**] had completed on December 31, 2025 without taking into account of any H Shares, which may be issued upon the exercise of the [**REDACTED**] and the [**REDACTED**]. See Appendix II to this document.

LEGAL PROCEEDINGS AND NON-COMPLIANCE

We may from time to time be subject to various legal or administrative claims and proceedings arising from the ordinary course of business. Litigation or any other legal or administrative proceeding, regardless of the outcome, is likely to result in substantial cost and diversion of our resources, including our management's time and attention. As of the Latest Practicable Date, other than the ongoing litigation relating to a contract dispute, we were not involved in any court, arbitral or administrative proceedings that are material to our assets and liabilities or profits and losses, nor, so far as we are aware, are any such proceedings pending or threatened against us. For further details relating to the contract dispute, please see "Business — Legal Proceedings And Compliance — Litigation in Relation to a Contract Dispute." During the Track Record Period and up to the Latest Practicable Date, we had not been and were not involved in any material non-compliance incidents that have led to fines, enforcement actions or other penalties that could, individually or in the aggregate, have a material adverse effect on our business, financial condition and results of operations.

RECENT DEVELOPMENTS AND NO MATERIAL ADVERSE CHANGE

Subsequent to the Track Record Period and up to the Latest Practicable Date, we have continued to execute our business strategies, achieving progress in both our commercial expansion and the advancement of our key pipeline products.

Research and Development Progress

In the first half of 2026, we have progressed smoothly in the clinical development of our vaccine candidates. In particular, our rFSAV, which is currently in a Phase III clinical trial, continues to advance as planned. Subsequent to the Track Record Period, our primary focus has been on the ongoing subject follow-up work. This progress is crucial for maintaining the integrity of the trial and ensures that we remain on schedule for the anticipated data unblinding in the third quarter of 2026, which will be a pivotal moment for this core pipeline asset.

Financial Position

After performing sufficient due diligence work which our Directors consider appropriate and after due and careful consideration, our Directors confirm that, up to the Latest Practicable Date, there has been no material adverse change in our financial or trading position or prospects since December 31, 2025, being the end date of the period reported on in the Accountants' Report as set out in Appendix I, and there is no event since December 31, 2025 which would materially affect the information as set out in the Accountants' Report in Appendix I to this document.